#ATRC

InsiderFinance

@insiderfinance.com

1 month ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CHKP, #PCVX, #BIDU, #ATRC, #BLDP

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

2 months ago

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 AtriCure (Nasdaq: ATRC) reported preliminary, unaudited Q4 2025 revenue of $140.5M (+13% YoY; +12% constant currency) and full-year 2025 revenue of $534.5M (+15% YoY; +14% constant currency). Q4 U.S. revenue was $114.3M and international was $26.2M. Management expects full-year 2025 adjusted EBITDA of $57M–$59M and adjusted loss per share of $0.18–$0.21. Cash and investments totaled about $167M at year-end. For 2026 the company projects revenue of $600M–$610M (+12%–14%), positive adjusted EBITDA of $80M–$82M, net income, and continued positive cash flow.

#ATRC AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026

www.stocktitan.net/news/ATRC/atri-cure-repo...

Steve Layton

@shindakun.net

3 months ago

Poll that no one will see...

Should I keep working on my #atrc #atproto IRC-ish chat concept? I mean there can never be too many chat apps right?

Steve Layton

@shindakun.net

3 months ago

atrc proof of concept image

Not sure there is anything new here but it's #atrc an IRC-like proof of concept, you still join a main "server" but anyone could host one in theory and all your msg data is stored in your PDS. This is two different servers and users on each federated together through the firehose. #atproto

StockTitan

@stocktitan.net

3 months ago

#ATRC AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

www.stocktitan.net/news/ATRC/atri-cure-anno...

StockTitan

@stocktitan.net

4 months ago

AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 AtriCure (Nasdaq: ATRC) reported Q3 2025 results: revenue $134.3M (+15.8% YoY; +15.1% constant currency), gross profit $101.3M and gross margin 75.5% (up 59 bps). Q3 net loss was $0.3M (basic/diluted loss $0.01), an improvement of $7.6M versus prior year. Adjusted EBITDA $17.8M (up $9.9M YoY). The company generated $30.1M cash in Q3 and reported cash and equivalents of $147.9M at Sept 30, 2025. Management raised full‑year 2025 guidance to $532M–$534M revenue, Adjusted EBITDA of $55M–$57M, and adjusted loss per share of $0.23–$0.26. A conference call was scheduled for Oct 29, 2025 at 4:30 PM ET.

#ATRC AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

www.stocktitan.net/news/ATRC/atri-cure-repo...

Joseph M. Edwards

@josephmedwards.bsky.social

4 months ago

still unreal to me.. #atrc

StockTitan

@stocktitan.net

7 months ago

AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025 AtriCure (NASDAQ:ATRC), a leader in surgical treatments for atrial fibrillation, reported strong Q2 2025 financial results and raised its outlook. The company achieved revenue of $136.1 million, up 17.1% year-over-year, with U.S. revenue at $110.6 million (+15.7%) and international revenue at $25.6 million (+23.3%).Key highlights include a net loss improvement to $6.2 million from $8.0 million year-over-year, and Adjusted EBITDA of $15.4 million, increasing by $7.6 million. The company generated $17.9 million in cash during the quarter and completed enrollment of 6,500 patients in the LeAAPS trial.AtriCure raised its 2025 guidance, now projecting full-year revenue of $527-533 million and Adjusted EBITDA of $49-52 million. The company expects modest cash flow generation for 2025.

#ATRC AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025

www.stocktitan.net/news/ATRC/atri-cure-repo...

StockTitan

@stocktitan.net

8 months ago

Landmark 6,500-Patient Trial Could Revolutionize Stroke Prevention in Cardiac Surgery Largest-ever cardiac device trial enrolls 6,500 patients across 137 centers, targeting stroke prevention for 1M+ surgery patients annually. See breakthrough potential.

#ATRC AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention

www.stocktitan.net/news/ATRC/atri-cure-comp...

StockTitan

@stocktitan.net

8 months ago

Leading Afib Treatment Innovator AtriCure Announces Q2 2025 Earnings Date - Key Details Inside AtriCure schedules Q2 earnings webcast for July 29 at 4:30 PM ET. Register now for insights from the surgical Afib treatment leader. Get details.

#ATRC AtriCure to Announce Second Quarter 2025 Financial Results

www.stocktitan.net/news/ATRC/atri-cure-to-a...

StockTitan

@stocktitan.net

10 months ago

AtriCure Reports First Quarter 2025 Financial Results AtriCure reported strong Q1 2025 financial results with worldwide revenue reaching $123.6 million, marking a 13.6% year-over-year increase. The company showed significant improvement in its net loss position, reducing it to $6.7 million from $13.3 million in the previous year. Key highlights include: U.S. revenue grew 12.1% to $101.1 million International revenue increased 20.8% to $22.5 million Gross margin improved to 74.9% Adjusted EBITDA reached $8.8 million, up by $6.0 million Growth was driven by strong sales across product lines, including the EnCompass clamp, cryoSPHERE MAX probes, and AtriClip Flex·Mini device. Management updated 2025 guidance, projecting full-year revenue between $517-527 million and adjusted EBITDA of $44-46 million.

#ATRC AtriCure Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/ATRC/atri-cure-repo...

StockTitan

@stocktitan.net

1 year ago

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results AtriCure (ATRC) reported strong financial results for Q4 and full-year 2024. Q4 revenue reached $124.3 million, up 16.6% year-over-year, while full-year revenue grew 16.5% to $465.3 million. U.S. revenue increased 14.4% to $101.6 million in Q4, driven by sales of cryoSPHERE probes, AtriClip Flex-V devices, and EnCompass clamp. International revenue rose 27.7% to $22.7 million.The company reported a Q4 net loss of $0.33 per share, compared to $0.21 in Q4 2023. Adjusted EBITDA was positive at $12.7 million for Q4 2024. For 2025, AtriCure projects revenue between $517-527 million and positive adjusted EBITDA of $42-44 million.Notable developments include the launch of new products: cryoSPHERE+, cryoSPHERE MAX, AtriClip FLEX-Mini in the U.S., and EnCompass clamp in Europe.

#ATRC AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

www.stocktitan.net/news/ATRC/atri-cure-repo...

StockTitan

@stocktitan.net

1 year ago

AtriCure Sets Q4 and Full Year 2024 Earnings Release Date for February 12 AtriCure, leader in atrial fibrillation surgical treatments, will announce Q4 and full year 2024 financial results, followed by investor webcast on February 12, 2025.

#ATRC AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/ATRC/atri-cure-to-a...

StockTitan

@stocktitan.net

1 year ago

AtriCure Reports Strong 17% Revenue Growth to $124.3M in Q4, Sets Ambitious 2025 Targets AtriCure delivers robust Q4 performance with $124.3M revenue, driven by cryoSPHERE and AtriClip growth. Company projects 2025 revenue up to $527M with improved EBITDA.

#ATRC AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

www.stocktitan.net/news/ATRC/atri-cure-repo...

StockTitan

@stocktitan.net

1 year ago

#ATRC AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/ATRC/atri-cure-to-p...

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #ATRC ) When (ATRC) Moves Investors should Listen

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #ATRC ) AtriCure Receives Expanded CE-Mark Indication for AtriClip Devices for the Reduction of Stroke in Patients with Atrial Fibrillation

#StockMarket #News

Carrington Malin

@carringtonmalin.bsky.social

2 years ago

ATRC to launch a series of new tech ventures Priorities for the next phase of the ATRC's work discussed in board meeting

Abu Dhabi's #ATRC to launch a series of new technology-driven ventures to capitalise on R&D outputs

#MiddleEastAINews

www.middleeastainews.com/p/atrc-to-la...